Protagonist Therapeutics, Inc
PTGXProtagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for various diseases. Founded with the aim of harnessing the potential of peptides as targeted and effective treatments, the company primarily advances programs in gastrointestinal and inflammatory diseases, leveraging proprietary peptide delivery platforms.
Company News
Moody Aldrich Partners LLC completely sold its entire 35,228 share position in Chart Industries, valued at approximately $5.8 million, reducing its reportable assets to zero in Q3 2025.
Moody Aldrich Partners LLC completely sold its entire 53,211 share position in Palomar Holdings for an estimated $8.21 million during Q3 2025, reducing its stake to zero, likely as part of routine portfolio rebalancing.
Johnson & Johnson demonstrated strong financial health in Q3, with 7% sales growth, $14.2 billion in free cash flow, and plans to separate its orthopedics business to focus on six priority growth areas. The company remains committed to dividend growth and oncology investments.
Johnson & Johnson reported strong Q3 2025 earnings, beating consensus estimates, and announced plans to separate its Orthopedics business into a standalone entity called DePuy Synthes within 18-24 months, targeting increased top-line growth and operating margins.
The FDA updated safety labeling for Johnson & Johnson's Carvykti cancer cell therapy, adding a warning about immune effector cell-associated enterocolitis, a serious complication with potential fatal outcomes. Despite the warning, regulators affirmed the therapy's benefits continue to outweigh its risks.
